Parnax Lab

Parnax Lab Equity Growth

The Year-over-Year Equity Growth of Parnax Lab (506128.BO) as of Nov 3, 2026 is 16.10 %. In the previous year, Year-over-Year Equity Growth was 15.15 % — a change of 6.27% (higher).

Equity Growth

16.10 %

YoY

6.27%

Last updated:

Year-over-Year Equity Growth of Parnax Lab is 2025 16.10 % . Year-over-Year Equity Growth of Parnax Lab was 2024 15.15 % . It decreases by 6.27% higher compared to the previous year.

The Parnax Lab Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
4.13 INR
Jan 1, 2019
9.90 INR
Jan 1, 2020
-8.22 INR
Jan 1, 2021
-0.77 INR
Jan 1, 2022
48.07 INR
Jan 1, 2023
28.99 INR
Jan 1, 2024
15.15 INR
Jan 1, 2025
16.10 INR
The Parnax Lab Equity Growth history
YEAREquity GrowthYoY
16.10 %+6.27%
15.15 %-47.72%
28.99 %-39.69%
48.07 %-6,371.06%
-0.77 %-90.67%
-8.22 %-182.98%
9.90 %+139.46%
4.13 %-68.08%
12.95 %+30.23%
9.95 %-51.06%
20.32 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Year-over-Year Equity Growth of Parnax Lab is 16.10 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Parnax Lab

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Parnax Lab